Product Specifications: - Compound: Wolverine Stack (BPC157, TB500 blend)
D.SenadheeraD
The AngioSafe 1 study, which is also designed to clarify the association between exposure to GLP-1R agonists and diabetic retinopathy through clinical and preclinical study designs found no risk for severe diabetic retinopathy when patients were treated with GLP-1R agonists, and no effect of GLP-1R agonists on angiogenesis ( Diabetic Retinopathy and Glucagon-Like Peptide 1 Agonists Previous studies, including the DCCT, SUSTAIN-6, LEADER and TECOS trials, have linked exposure to incretin-based therapies and other hypoglycemic agents (i.e., insulin , injectable semaglutide, liraglutide , and oral sitagliptin ) to the exacerbation of pre-existing retinopathy (No authors listed, 1998, 1999
Se conoce poco sobre los mecanismos moleculares que causan estos procesos
Hims uses the standard FDA criteria for GLP-1s: a BMI of 30+, or 27+ if you have a related condition like diabetes or high blood pressure
*Dependent on the extent of renal dysfunction and age of the patient